Evidence map›Paper›PMID 33259011›Full record

ArticleMolecular biology reports2020

Lipid profile: causal relationship on cognitive performance in multiple sclerosis?

Ana Laura Hernández-Ledesma, Adriana Jheny Rodríguez-Méndez, Lilia Susana Gallardo-Vidal, Teresa García-Gasca, Julia María Alatorre-Cruz, Pablo García-Solís, Julián López Reyes, Juan Carlos Solís-Saínz

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ana Laura Hernández-LedesmaLaboratorio de Neuroinmunoendocrinología, Departamento de Investigación Biomédica, Facultad de Medicina, Universidad Autónoma de Querétaro, Clavel #200. Prados de la Capilla. CP 76170, Santiago de Querétaro, México.ORCID http://orcid.org/0000-0002-8819-7471
Adriana Jheny Rodríguez-MéndezLaboratorio de Neuroinmunoendocrinología, Departamento de Investigación Biomédica, Facultad de Medicina, Universidad Autónoma de Querétaro, Clavel #200. Prados de la Capilla. CP 76170, Santiago de Querétaro, México. jheny.rodriguez@uaq.mx.ORCID http://orcid.org/0000-0002-6438-3181
Lilia Susana Gallardo-VidalUnidad de Medicina Familiar No. 13, Instituto Mexicano de Seguro Social, Querétaro, México.
Teresa García-GascaFacultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Santiago de Querétaro, México.
Julia María Alatorre-CruzFacultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Santiago de Querétaro, México.
Pablo García-SolísDepartamento de Investigación Biomédica, Facultad de Medicina, Universidad Autónoma de Querétaro, Santiago de Querétaro, México.
Julián López ReyesFacultad de Medicina, Clínica del Sistema Nervioso, Universidad Autónoma de Querétaro, Santiago de Querétaro, México.
Juan Carlos Solís-SaínzDepartamento de Investigación Biomédica, Facultad de Medicina, Universidad Autónoma de Querétaro, Santiago de Querétaro, México.
Autonomous University of Queretaro · MXMexican Social Security Institute · MX

Funding

CONACYT Graduated Fellowship 586155FONDOS DE PROYECTOS ESPECIALES DE RECTORIA FOPER 2017 Y FOPER 2018-00475
6 · The paper itself

Abstract

Although cognitive impairment (CI) is classically associated with aging, it has been proposed that neurological pathologies may increase the risk to suffer CI. Despite the evidence of an elevated prevalence of CI in patients with multiple sclerosis (MS), it is not considered among standard clinical evaluations, due the lack of specialists and time required. The aim of this study was to evaluate if lipid profile is associated with cognitive performance in persons with MS. Twenty patients with MS were evaluated. Montreal Cognitive Assessment (MoCA) was employed to determine cognitive performance. CI was observed in 85% of patients, with memory recall and language as the most affected domains. Despite biomarkers were mostly found within reference values, several correlations were observed. MoCA total score was correlated with cholesterol (r =  - 0.468, p = 0.037) and LDL (r =  - 0.453, p = 0.045). Visuospatial domain was correlated with LDL (r =  - 0.493, p = 0.027). Attention domain correlated with triglycerides (r =  - 0.455, p = 0.044) and cholesterol (r =  - 0.549, p = 0.012). When the person reaches borderline levels of triglycerides, LDL and cholesterol a decrease in cognitive performance can be observed. The mechanism underlying this association has not been established still, it has been proposed that it could be linked with neuroinflammation, alterations in synapses and in the metabolism of amyloid-β protein. This study settles the potential importance that lipid profile could have on cognitive performance in MS. Further studies are needed to establish optimal levels and implication of lipid profile in the diagnosis and monitoring of cognitive performance in Mexican people with MS.

Indexed as

AdultBiomarkersCholesterol, HDLCholesterol, LDLCholesterol, VLDLCognitionCognitive DysfunctionFemaleGlatiramer AcetateHumansImmunologic FactorsInterferonsLipidomicsMaleMiddle AgedMultiple SclerosisBiomarkersCholesterol, HDLCholesterol, LDLCholesterol, VLDLGlatiramer AcetateImmunologic FactorsInterferonsTriglyceridesBiomarkerCognitive impairmentLipid profileMultiple sclerosis

Identifiers

PMID33259011
OpenAlexW3107459770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.